Results 21 to 30 of about 11,830 (209)

A report on the potential of Rac1/pSTAT3 protein levels in T lymphocytes to assess the pharmacodynamic effect of thiopurine therapy in Inflammatory Bowel Disease patients

Scientific Reports, 2022
The thiopurine derivatives azathioprine (AZA), mercaptopurine (MP) and tioguanine (TG) remain standard treatment of inflammatory bowel disease (IBD). The immune suppressive effect of thiopurines is primarily based on blocking the Ras-related C3 botulinum
Debbie S. Deben, Rob H. Creemers, Arjan J. van Adrichem, Roosmarie Drent, Audrey H. H. Merry, Mathie P. G. Leers, Adriaan A. van Bodegraven, Dennis R. Wong   +7 more
doaj   +1 more source

The Inhibitory Effects of 6-Thioguanine and 6-Mercaptopurine on the USP2a Target Fatty Acid Synthase in Human Submaxillary Carcinoma Cells

Frontiers in Oncology, 2021
Overexpression of the deubiquitinase USP2a leads to stabilization of fatty acid synthase (FAS), the levels of which are often elevated in aggressive human cancers.
Chiao-Pei Cheng, Shu-Ting Liu, Yi-Lin Chiu, Shih-Ming Huang, Ching-Liang Ho   +4 more
doaj   +1 more source

A primary hepatic lymphoma in a patient with Crohn's disease receiving thiopurine and anti-TNF therapy: a case report

Future Science OA, 2023
Primary hepatic lymphoma is a rare variant of non-Hodgkin's lymphoma with an incidence of 0.016% of all non-Hodgkin lymphomas. The most common histologic subtype is large diffuse B-cell lymphoma.
Salma Merhaben, Shema Ayadi, Monia Tangour, Nadia Boujelbene, Rayfa Ghariani, Leila Mouelhi, Fathi Merhaben   +6 more
doaj   +1 more source

Risk-stratified monitoring for thiopurine toxicity in immune-mediated inflammatory diseases: prognostic model development, validation, and, health economic evaluation [PDF]

, 2023
Background: Patients established on thiopurines (e.g., azathioprine) are recommended to undergo three-monthly blood tests for the early detection of blood, liver, or kidney toxicity. These side-effects are uncommon during long-term treatment.
Riley, R.D., Richard D. Riley, Grainge, Matthew J, Williams, H.C., Nakafero, G., Georgina Nakafero, Taal, M.W., Guruprasad P. Aithal, Nakafero, Georgina, Abhishek Abhishek, Grainge, M.J., Maarten W. Taal, Christopher P. Fox, Hywel C. Williams, Abhishek, Abhishek, Matthew D. Stevenson, Mallen, Christian D, van der Windt, Danielle A, van der Windt, D.A., Aithal, G.P., Mallen, C.D., Stevenson, Matthew D, Tim Card, Fox, Christopher P, Aithal, Guruprasad P, Danielle A. van der Windt, Abhishek, A., Christian D. Mallen, Card, Tim, Williams, Hywel C, Card, T., Fox, C.P., Matthew J. Grainge, Taal, Maarten W, Riley, Richard D, Stevenson, M.D.   +35 more
core   +1 more source

Usefulness and difficulties with the thiopurine pharmacogenomic NUDT15 genotyping test: Analysis of real-world data in Japan

Journal of Pharmacological Sciences, 2023
The usefulness of NUDT15 genotyping as a pharmacogenomic test for thiopurine has been established. The first such test developed to date, NUDT15 genotyping was approved for reimbursement in Japan in February 2019 for all indicated patients.
Yoichi Kakuta, Motohiro Kato, Yusuke Shimoyama, Takeo Naito, Rintaro Moroi, Masatake Kuroha, Hisashi Shiga, Yoshitaka Kinouchi, Atsushi Masamune   +8 more
doaj   +1 more source

Long-term efficacy and tolerability of dose-adjusted thiopurine treatment in maintaining remission in inflammatory bowel disease patients with heterozygosity [PDF]

Intestinal Research, 2022
Background/Aims Thiopurines are key drugs for inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn’s disease (CD). Recently, NUDT15 polymorphism (R139C, c.415C > T) has been shown to be associated with thiopurine-induced adverse ...
Takato Maeda, Hirotake Sakuraba, Hiroto Hiraga, Shukuko Yoshida, Yoichi Kakuta, Hidezumi Kikuchi, Shogo Kawaguchi, Keisuke Hasui, Tetsuya Tatsuta, Daisuke Chinda, Tatsuya Mikami, Shinsaku Fukuda   +11 more
doaj   +1 more source

Biomarkers Predictive of Response to Thiopurine Therapy in Inflammatory Bowel Disease

Frontiers in Medicine, 2020
The complex nature of inflammatory bowel disease (IBD) often results in treatment failure for many patients. With some patients cycling through multiple therapies before achieving a sustained period of remission, the ability to predict a patient's ...
Jack S. Cornish, Elisa Wirthgen, Jan Däbritz, Jan Däbritz   +3 more
doaj   +1 more source

Thiopurines in Inflammatory Bowel Disease. How to Optimize Thiopurines in the Biologic Era? [PDF]

Frontiers in Medicine, 2021
Thiopurines have been a cornerstone in the treatment of inflammatory bowel disease (IBD). Although they have been used for more than 50 years, there are still some unsolved issues about their efficacy and, also, some safety concerns, mainly the risk of myelosuppression and life-threatening lymphoproliferative disorders.
Carla J. Gargallo-Puyuelo, Viviana Laredo, Fernando Gomollón, Fernando Gomollón, Fernando Gomollón, Fernando Gomollón   +5 more
openaire   +5 more sources

Pharmacogenetics of thiopurines

Cancer Drug Resistance, 2019
Polychemotherapeutic protocols for the treatment of pediatric acute lymphoblastic leukemia (ALL) always include thiopurines. Specific approaches vary in terms of drugs, dosages and combinations. Such therapeutic schemes, including risk-adapted intensity, have been extremely successful for children with ALL who have reached an outstanding 5-year ...
Raffaella Franca, ZUDEH, GIULIA, Sofia Pagarin, Marco Rabusin, Marianna Lucafò, Gabriele Stocco, Giuliana Decorti   +6 more
openaire   +3 more sources

Revisiting the Role of Thiopurines in Inflammatory Bowel Disease Through Pharmacogenomics and Use of Novel Methods for Therapeutic Drug Monitoring

Frontiers in Pharmacology, 2018
Azathioprine and 6-mercaptopurine, often referred to as thiopurine compounds, are commonly used in the management of inflammatory bowel disease. However, patients receiving these drugs are prone to developing adverse drug reactions or therapeutic ...
Sheng Zhang Lim, Eng Wee Chua
doaj   +1 more source